A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)

Eye (Basingstoke)

Volumn 29, Issue 12, 2015, Pages 1603-1612

  Ramu, J ^a   Yang, Y ^b   Menon, G ^c   Bailey, C ^d   Narendran, N ^b   Bunce, C ^a   Quartilho, A ^a   Prevost, A T ^e   Hykin, P ^a   Sivaprasad, S ^a  

^a Moorfields NIHR Ophthalmology Biomedical Research Centre   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^c FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d BRISTOL EYE HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; DEXAMETHASONE; HEMOGLOBIN A1C; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAOCULAR PRESSURE ABNORMALITY; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL; REFRACTORY DIABETIC MACULAR EDEMA; RETINA DETACHMENT; SUBCAPSULAR CATARACT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DRUG IMPLANT; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETREATMENT;

AGED; DEXAMETHASONE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84949568886     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.214     Document Type: Article

References (19)

1. Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol 2012; 19(1): 4-12.
2. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
3. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris III FL, Friedman SM et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
4. Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 2012; 130: 1153-1161.
5. Sivaprasad S, Crosby-Nwaobi R, Esposti SD, Peto T, Rajendram R, Michaelides M et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4). PLoS One 2013; 8(8): e72755.
6. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 2012; 26(4): 485-493.
7. Diabetic Retinopathy Clinical Research Network (DRCR. net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127(3): 245-251.
8. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep 2012; 12(4): 364-375.
9. Boyer DS, Yoon YH, Belfort Jr R, Bandello F, Maturi RK, Augustin AJ et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121(10): 1904-1914.
10. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120(9): 1843-1851.
11. Mathew R, Pearce E, Muniraju R, Abdel-Hay A, Sivaprasad S. Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). Eye (Lond) 2014; 28(3): 318-326.
12. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121(12): 2473-2481.
13. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119(7): 1050-1058.
14. Brose LS, Bradley C. Psychometric development of the retinopathy treatment satisfaction questionnaire (RetTSQ). Psychol Health Med 2009; 14(6): 740-754.
15. Brose LS, Bradley C. Psychometric development of the individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL). Value Health 2010; 13(1): 119-127.
16. Wilkinson CP, Ferris 3rd FL, Klein RE, Lee PP, Agardh CD, Davis M et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110(9): 1677-1682.
17. Chylack Jr LT, Leske MC, Sperduto R, Khu P, McCarthy D. Arch Ophthalmol 1988; 106(3): 330-334.
18. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399-2405.
19. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.